Literature DB >> 17418999

Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells.

Caroline Bonnans1, Delphine Gras, Claude Chavis, Brigitte Mainprice, Isabelle Vachier, Philippe Godard, Pascal Chanez.   

Abstract

In this study, we investigated the synthesis of lipoxins (LXs) and their anti-inflammatory effects in different human airway epithelial cell culture models. After cell incubation with exogenous 5(S),6(R)-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid, LXA(4) was detected in supernatants of differentiated human bronchial epithelial cells by contrast to non-differentiated cells. Exogenous LXA(4) significantly inhibited tumor necrosis factor-alpha (TNF-alpha)-induced interleukin-8 (IL-8) release in the different epithelial cell types and the potency of inhibition was dependent of the accessibility of the specific LXA(4) receptor, formyl-peptide receptor like-1 (FPRL-1) expressed by all these cells. Immunohistochemistry analysis on human bronchial biopsies showed a high expression of FPRL-1 in the epithelium. Finally, an FPRL-1 receptor antagonist, boc-2 peptide reversed LXA(4) effect on IL-8 generation. Together, these findings indicate that differentiated human bronchial epithelium synthesizes LX in vivo which could have autocrine actions through its specific receptor FPRL-1 to promote resolution of airway inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418999     DOI: 10.1016/j.biopha.2007.02.016

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  16 in total

1.  Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation.

Authors:  Oliver Haworth; Manuela Cernadas; Rong Yang; Charles N Serhan; Bruce D Levy
Journal:  Nat Immunol       Date:  2008-06-22       Impact factor: 25.606

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

3.  Strict Regiospecificity of Human Epithelial 15-Lipoxygenase-2 Delineates Its Transcellular Synthesis Potential.

Authors:  Abigail R Green; Shannon Barbour; Thomas Horn; Jose Carlos; Jevgenij A Raskatov; Theodore R Holman
Journal:  Biochemistry       Date:  2016-05-13       Impact factor: 3.162

Review 4.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

5.  Primary human airway epithelial cell-dependent inhibition of human lung mast cell degranulation.

Authors:  Neil Martin; Andrew Ruddick; Greer K Arthur; Heidi Wan; Lucy Woodman; Christopher E Brightling; Don J L Jones; Ian D Pavord; Peter Bradding
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

6.  Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia.

Authors:  Valia Verrière; Gerard Higgins; Mazen Al-Alawi; Richard W Costello; Paul McNally; Raphaël Chiron; Brian J Harvey; Valérie Urbach
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

7.  AT-RvD1 modulates CCL-2 and CXCL-8 production and NF-κB, STAT-6, SOCS1, and SOCS3 expression on bronchial epithelial cells stimulated with IL-4.

Authors:  Jhony Robison de Oliveira; Daniely Cornélio Favarin; Sarah Cristina Sato Vaz Tanaka; Marly Aparecida Spadotto Balarin; David Nascimento Silva Teixeira; Bruce David Levy; Alexandre de Paula Rogério
Journal:  Biomed Res Int       Date:  2015-05-05       Impact factor: 3.411

Review 8.  The role of Lipoxin A4 in Cystic Fibrosis Lung Disease.

Authors:  Valérie Urbach; Gerard Higgins; Paul Buchanan; Fiona Ringholz
Journal:  Comput Struct Biotechnol J       Date:  2013-12-06       Impact factor: 7.271

9.  Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.

Authors:  Emma Börgeson; Catherine Godson
Journal:  Front Immunol       Date:  2012-10-18       Impact factor: 7.561

10.  A role for lipoxin A₄ as an anti-inflammatory mediator in the human endometrium.

Authors:  Linsay J Macdonald; Sheila C Boddy; Fiona C Denison; Kurt J Sales; Henry N Jabbour
Journal:  Reproduction       Date:  2011-05-09       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.